Trials / Completed
CompletedNCT06894771
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-4700 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-4700 | Administered via subcutaneous (SC) injection |
| BIOLOGICAL | Pembrolizumab | Administered via intravenous infusion |
Timeline
- Start date
- 2025-04-23
- Primary completion
- 2025-12-08
- Completion
- 2025-12-08
- First posted
- 2025-03-25
- Last updated
- 2026-03-16
Locations
7 sites across 3 countries: United States, Canada, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06894771. Inclusion in this directory is not an endorsement.